Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (74,444)	$ (106,754)
Income (loss) from discontinued operations	3,230	(1,421)
Loss from continuing operations	(77,674)	(105,333)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Depreciation and amortization	3,558	4,406
Net amortization of premiums on marketable securities	127	908
Amortization of debt discount and loan fees	1,969	1,900
Debt conversion expense	5,027	0
Warrant expense related to vesting of ADM Warrant	0	72
Provision for doubtful accounts	321	0
Non-cash restructuring charges	0	372
Stock-based compensation expense	8,961	11,533
Loss from equity method investments	16,608	17,896
Change in fair value of derivative liabilities	(82)	(27)
Changes in operating assets and liabilities:
Accounts receivable	(1,530)	(2,970)
Inventories	(703)	2,252
Prepaid expenses and other assets	(184)	5
Accounts payable	(766)	(278)
Accrued liabilities	(1,151)	(1,651)
Deferred revenue	1,285	77
Other current and long-term liabilities	679	4,875
Net cash used in operating activities — continuing operations	(45,394)	(65,963)
Net cash used in operating activities — discontinued operations	(4,107)	(3,057)
Net cash used in operating activities	(49,501)	(69,020)
Investing activities:
Purchases of property, plant and equipment	(1,488)	(942)
Proceeds from the sale of equipment	0	119
Purchases of marketable securities	(2,707)	(23,349)
Maturities of marketable securities	22,665	86,952
Proceeds from sales of marketable securities	3,331	31,277
Capital contributions to Solazyme Bunge JV	(7,798)	(19,494)
Restricted certificates of deposit	0	181
Net cash provided by investing activities — continuing operations	14,003	74,744
Net cash provided by (used in) investing activities — discontinued operations	19,065	(220)
Net cash provided by investing activities	33,068	74,524
Financing activities:
Proceeds from the issuance of common stock	2,291	720
Proceeds from issuance of preferred stock, net of offering costs	27,044	0
Other	0	(38)
Net cash provided by financing activities	29,335	682
Effect of exchange rate changes on cash and cash equivalents	159	(633)
Net increase in cash and cash equivalents	13,061	5,553
Cash and cash equivalents - beginning of period	46,966	42,689
Cash and cash equivalents - end of period	60,027	48,242
Supplemental disclosures of cash flow information:
Interest paid in cash, net of capitalized interest	7,311	7,438
Non-cash investing and financing activities:
Unpaid closing costs on sale of discontinued operations	228	0
Non-cash issuance of common stock options for offering costs	335	0
Issuance of common stock to settle restructuring liabilities	1,205	0
Convertible debt exchanged	12,671	0
Issuance of common stock	$ 16,298	$ 0